After decades of antipsychotic drugs, a new FDA-approved treatment for schizophrenia targets a different brain system—with ...

Cobenfy, a new drug made by Bristol Myers Squibb and approved by the FDA last week, triggers muscarinic receptors instead of dopamine receptors. It's the first schizophrenia treatment to do so.

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.

The FDA approved xanomeline and trospium chloride (Cobenfy) capsules, the first antipsychotic medication for schizophrenia that targets cholinergic receptors instead of the traditional dopamine ...

But Bristol Myers Squibb's new drug will indirectly target the dopamine receptors by targeting the neurochemical acetylcholine to inhibit the activity of cholinergic receptors, which play an ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach. By Ellen Barry and Christina Jewett The Food and Drug Administration on ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.

Other medicines that are used to treat schizophrenia bind to receptors that decrease the amount of a different chemical called dopamine. Because Cobenfy works differently than other schizophrenia ...

Typically, the standard of care for schizophrenia has focused on dopamine, a vital neurotransmitter in the brain. In the case of psychosis, too much dopamine signaling could be to blame, ...

Unlike existing medications that target dopamine receptors, this oral medication focuses on cholinergic receptors. ... Schizophrenia is a chronic mental health disorder that affects how a ...

The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia.The drug targets cholinergic receptors as opposed ...

Sept. 26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday. The drug, generically called Cobenfy, is the first oral ...